PCVX VAXCYTE INC Product Launches 8-K Filing 2025 - Vaccine Update On March 31, 2025, Vaxcyte, Inc. announced positive results from its Phase 2 study of VAX-24, a vaccine for invasive pneumococcal disease, and mentioned ongoing development of VAX-XL.Get access to all SEC 8-K filings of the VAXCYTE INC